Prognostic Value of p21WAF1 and p53 Expression in Breast Carcinoma: An Immunohistochemical Study in 261 Patients with Long-Term Follow-Up

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1591-1599

  Caffo, Orazio ^a   Doglioni, Claudio ^b   Veronese, Silvio ^c   Bonzanini, Mariella ^a   Marchetti, Antonio ^d   Buttitta, Fiamma ^d   Fina, Paolo ^e   Leek, Russell ^f   Morelli, Luca ^a   Dalla Palma, Paolo ^a   Harris, Adrian L ^f   Barbareschi, Mattia ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b Hospital of Belluno   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e GSK   (Italy)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; PROTEIN P53;

ADULT; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL; TIME; TUMOR RECURRENCE;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030223056     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
2. Xiong, Y., Hannon, G. J, Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 360: 701-707, 1993
3. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
4. Sheikh, M. S., Li, S. X., Shao, Z. M., Ordonez, J. V., and Fontana, J. A. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene, 9: 3407-3414, 1994.
5. Russo, T., Zarabrang, N, Esposito, F., Ammendola, R., Cimino, F, Fiscella, M., Jackman, J., O'Connor, P. M., and Appella, E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem., 270: 29386-29391, 1995.
6. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A., and El-Houseini, M. E. E. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene, 9: 3389-3396, 1994.
7. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
8. Zhang, W., Grasso, L., McClain, G. D., Gambel, A. M, Cha, Y., Travali, S., Deisseroth, A. B, and Mercer, W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55: 668-674, 1995.
9. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.
10. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Dalla Palma, P., and Bevilacqua, G. p21/WAF1 expression in lung carcinomas, association with differentiation. Oncogene, 12. 1319-1324, 1996.
11. Doglioni, C., Pelosio, P., Laurino, L., Macri', E., and Barbareschi, M. p21/WAF1/CIP1 expression in normal mucosa, adenomas and adenocarcinomas of the colon. J. Pathol., 179: 248-253, 1996.
12. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. I., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
13. Barbareschi, M., Caffo, O, Doglioni, C., Marchetti, A., Buttitta, F., Leek, R., Bevilacqua, G., Dalla Palma, P., and Harris, A. L. p21Waf1 immunohistochemical expression in breast carcinoma: correlation with clinic-pathologic data, ER status, MIB1 expression, p53 gene and protein alteration and relapse free survival Br. J. Cancer, in press, 1996.
14. Lowe, S. W., Bodis, S., Mcclatchey, A., Remington, L, Ruley, H. E, Fisher, D. E, Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-811, 1994.
15. WAF1 and p53 requires c-raf-1. Cancer Res., 55: 4623-4626, 1995.
16. 1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res., 55: 2075-2080, 1995.
17. Vikhanskaya, F., Dincalci, M, and Broggini, M Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int. J. Cancer, 61: 397-401, 1995.
18. Rosen, P. P., and Oberman, H. A. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology, 1993.
19. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. The evaluation of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology, 19: 403-410, 1991.
20. Milner, J. DNA damage, p53 and anticancer therapies Nat. Med., 1: 879-888, 1995
21. Koechli, O. R., Schaer, G. N., Seifert, B., Hornung, R., Haller, U., Eppenberg, U., and Mueller, H. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet, 344: 1647-1648, 1994.
22. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K, Davidson, N. E., Robert, N., Torrney, D. C., and Allred, D. C. Accumulation of p53 protein as a possible predictor of response to adjuvant therapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J Natl. Cancer Inst., 87: 1254-1256, 1995.
23. Makris, A., Powles, T J., Dowsett, M., and Allred, C. p53 overexpression and chemosensitivity in breast cancer Lancet, 345: 1181-1182, 1995.
24. Mathieu, M. C., Koscienly, S., Le Bihan, M. L., Spielman, M., and Arrigada, R. p53 protein overexpression and chemosensitivity in breast cancer. Lancet, 345: 1182, 1995.
25. Elbendary, A., Berchuck, A., Davis, P., Havrilesky, L., Bast, R C., Inglehart, J. D., and Marks, J. R. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth & Differ., 5: 1301-1307, 1994.
26. Fan, Z, Lu, Y., Wu, X. P, Deblasio, A., Koff, A., and Mendelsohn, J. Prolonged induction of p21(Cip1/WAF1)/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J. Cell Biol., 131: 235-242, 1995.
27. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X. F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
28. Gorsch, S. M, Memoli, V. A., Stukel, T. A., Gold, L. I., and Arrick, B. A Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res., 52: 6949-6952, 1992.
29. WAF1/CIP1 in breast epithelial cells Cancer Res., 55: 4520-4524, 1995.
30. Gasparini, G., Barbareschi, M., Doglioni, C., Dalla Palma, P., Mauri, F A, Boracchi, P., Bevilacqua, P., Caffo, O., Pezzella, F., and Harris. A. L. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1: 189-198, 1995.
31. Barbareschi, M., Caffo, O., Veronese, S., Leek, R., Fox, S., Pezzella, F., Doglioni, C., Dalla Palma, P., and Harris, A. L. Bcl2 and p53 expression in node negative breast carcinoma: a study with long term follow-up. Hum. Pathol., in press, 1996.
32. 1 checkpoint control. Cell, 82: 675-684, 1995.
33. Fan, S, Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., O'Connor, P M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995
34. 2/M arrest and apoptosis Nat Med, 2: 72-73, 1996
35. 1 cell cycle arrest and transactivation of WAF1 and bax. Cell Growth & Differ., 6: 1071-1075, 1995.
36. Yang, Z. Y., Perkins, N. D, Ohno, T, Nabel, E. G., and Nabel, G. J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med., 1: 1052-1056, 1995.
37. Tahara, H., Sato, E., Noda, A., and Ide, T. Increase in expression level of p21/sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblast. Oncogene, 10: 835-840, 1995
38. Sheikh, M. S., Rochefort, H., and Garcia, M. Overexpression of p21 (WAF1/CIP1) induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene, 11: 1899-1905, 1995.
39. Barboule, N., Mazars, P., Baldin, V., Vidal, S., Jozan, S, Martel, P., and Valette. A Expression of p21 (WAF1/CIP1) is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer, 63: 611-615, 1995.
40. Hermeking, H., Funk, J. O., Reichert, M., Ellwart, J W., and Eick, D Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21 (WAF1/CIP1/SDI1). Oncogene, 11: 1409-1415, 1995
41. 1 arrest. Proc. Natl. Acad. Sci. USA, 91: 10079-10083, 1994
42. Bond, J. A., Blaydes, J. P., Rowson, J., Haughton, M. F., Smith, J. R., Wynfordthomas, D., and Wyllie, F. S. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/ WAF1. Cancer Res. 55: 2404-2409, 1995